Upload
phunghanh
View
216
Download
2
Embed Size (px)
Citation preview
Terapias anti CTLA-4
Curso Básico de Inmunología e Inmunoterapia y cáncer
Alfonso Berrocal
Hospital General Valencia
Mecanismo de acción
Teoría Tres señales: Co-estimulación
Interacción B7/CD28
• CD28 se expresa constitutivamente en linfocitos CD4 y CD8 naive
• Su función es coestimulatoria tras ligarse a B7 1 y 2
• CTLA-4 se induce tras la estimulación y frena respuesta inmune
• La expresión de B7 1 y 2 es regulada por el estado de activación de la APC
Mecanismo de acción anti CTLA-4
Célula T
TCR CTLA4
APC
MHC
CD28
B7
Inhibición Célula T
Célula T
TCR CD28
CTLA4
APC
MHC B7
Activación Célula T
Célula T
TCR
CTLA4
APC
MHC B7
Potenciación Célula T
IPILIMUMAB bloquea CTLA-4
Ipilimumab y T-regs
OX40 e Ipilimumab y T-regs
Tipos inmunoglobulinas
Tremelimumab IgG2 sin ADCC
Eficacia en la clinica
Perspectiva histórica de Ipilimumab
1991
1990 1995 2000 2005 2010
UC Berkeley team hypothesizes that blocking CTLA-4 could potentiate
immune system to fight cancer
1996
BMS Seattle team identifies CTLA-4
as target for impacting immune
system
First phase 1 trial for ipilimumab in prostate cancer
2000
Medarex develops first fully human
monoclonal antibody to block
CTLA-4
1999
BMS acquires Medarex gaining
full rights to ipilimumab
2009
BMS and Medarex enter agreement to co-develop & co-
commercialize ipilimumab
2004
Ipilimumab approved for
metastatic melanoma
2011
First phase 3 data presented in ipilimumab in
metastatic melanoma
2010
Eficacia en Melanoma
Median OS, months 95% CI HR P value
Survival rate (%)
1-year 2-year
Ipilimumab + gp100 10.0 8.5–11.5 0.68 <0.001 43.6 21.6
Ipilimumab 10.1 8.0–13.8 0.66 0.003 45.6 23.5
gp100 6.4 5.5–8.7 25.3 13.7
Pro
po
rtio
n o
f p
atie
nts
aliv
e (
%)
Years
0
20
40
60
80
100
0 1 2 3 4
• Ipilimumab was the first therapy for unresectable or metastatic melanoma to improve overall survival in a phase 3 trial1
Hodi FS, et al. N Engl J Med 2010;363:711–723
Primary Analysis of Pooled OS Data: 1861 Patients
Patients at Risk
Ipilimumab 1861 839 370 254 192 170 120 26 15 5 0
Pro
po
rtio
n A
live
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Months
0 12 24 36 48 60 72 84 96 108 120
Median OS, months (95% CI): 11.4 (10.7–12.1)
3-year OS rate, % (95% CI): 22 (20–24)
Ipilimumab
CENSORED
Schadendorf D, et al. Eur J Cancer 2013;49(suppl 2): abstract 24LBA
Analisis subgrupos SG (N=1861)
Naive 604 301 106 74 64 60 18 1 0 0 0
Pretratados 1257 538 264 180 128 110 102 25 15 5 0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 12 24 36 48 60 72 84 96 108 120
Treatment-naive
CENSORED
Previously Treated
CENSORED
Meses
Pro
po
rció
n v
ivo
s
Pacientes en Riesgo 3 mg/kg 965 429 127 73 41 29 28 12 8 4 0 10 mg/kg 706 316 191 145 118 111 64 2 0 0 0 Otros 190 94 52 36 33 30 28 12 7 1 0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 12 24 36 48 60 72 84 96 108 120
10 mg/kg
CENSORED
Other
CENSORED
3 mg/kg
CENSORED
Pro
po
rció
n v
ivo
s
Meses
Mediana, meses (95% CI)
Tasa SG 3 años,%
(95% CI)
Naive 13.5 (11.9, 15.4) 26 (21, 30)
Pretratados 10.7 (9.6, 11.4) 20 (18, 23)
Mediana, meses (95% CI)
Tasa SG 3 años, % (95% CI)
3 mg/kg 11.4 (10.3, 12.5) 21 (17, 24)
10 mg/kg 11.1 (9.9, 13.0) 24 (21, 28)
Other 12.4 (10.4, 15.1) 20 (14, 26)
• Por tratamiento previo • Por dosis
Schadendorf D, et al. Eur J Cancer 2013;49(suppl 2): abstract 24LBA
Los datos de LTS son consistentes con diferentes dosis y regímenes de tratamiento
Total N > 240 Phase I/II studies (Pre-chemo, TXT eligible, TXT failure)
Phase III: Single-dose XRT ± ipilimumab (n = 800) Survival
Phase II: Paclitaxel/carboplatin ± ipilimumab NSCLC (n = 210) irPFS SCLC (n = 210) irPFS
Phase III: ipilimumab vs placebo (n = 600) Survival
Phase III: Paclitaxel/carboplatin ± ipilimumab NSCLC (n = 920) Survival
Phase III: Etoposide/platinum ± ipilimumab SCLC (n = 1100) Survival
Phase II Gastric Ca
Phase II Ovarian Ca Study 201
Study 162 (n = 114) irPFS
Other development programs
NSCLC/SCLC
Prostate
7 Phase I/II Studies
Study 043 (post-tax)
Study 041
Study 095 (chemo-naïve)
Study 104
Study 156
Ipilimumab en otros tumores
Pancreas, Glioma, Hodgkin, Head and Neck, Cervix, Lymphoma, Breast, Renal, Sarcoma, GIST, Merckel….
Other
Próstata 043 (Post TAX) Ipi
(n=399) Pbo
(n=400)
Median OS, mo (95% CI) 11.2 (9.6–12.6) 10.0 (8.4–11.2)
HR (95% CI) 0.84 (0.72–0.98)
Stratified log-ranka P=0.03
1-yr OS rate 47% 41%
2-yr OS rate 25% 17%
3-yr OS rateb 12% 6%
Supervivencia NSCLC
Lynch T, et al. J Clin Oncol 2012;30(17):2046-54
Características especiales de respuesta y toxicidad
Ipilimumab response patterns
150
125
100
75
50
25
0
-25
-50
-75
-100
-125
19,373
17,242
15,111
12,980
10,849
8,718
6,587
4,456
2,325
194
-1,937
SPD
(mm
2)
Week after initial dose
50
25
0
–25
–50
–75
–100
–125
Ch
ange
fro
m b
ase
line
SP
D (
%)
Week after initial dose
1,272
1,124
975
827
678
530
382
233
85
-64
-212
SPD
(mm
2)
Ch
ange
fro
m b
ase
line
SP
D (
%)
-9 -3 3 9 15 21 27 33 39 45 51
Week after initial dose
Ch
ange
fro
m b
ase
line
SP
D (
%)
SPD
(mm
2)
2,894
2,556
2,218
1,881
1,543
1,206
868
530
193
-145
-482
50
25
0
-25
-50
-75
-100
-125
Total tumor volume
Index lesion
New lesions
Ipilimumab
SPD = Sum of the Product of the perpendicular Diameters (a measure of tumor volume)
-9 -3 3 9 15 21 27 33 39 45 51
-9 -3 3 9 15 21 27 33 39 45 51
Stable disease with slow
reduction in tumor volume
Response after an initial increase in tumor volume
Response in basal lesions
Ch
ange
fro
m b
ase
line
SP
D (
%)
SPD
(mm
2)
2,810
2,482
2,154
1,826
1,498
1,171
843
515
187
-140
-468
50
25
0
-25
-50
-75
-100
-125
-9 -3 3 9 15 21 27 33 39 45 51
9 months
Week after initial dose
PD
PR
CR
5.2 months 6 months
9.4 Months
Response after new lessions
aparition
Wolchok J, et al. Clin Cancer Res 2009;15:7412–7420
Criterios de respuesta inmune irRC
* **
Adapted from Wolchok et al. 2009
Adapted from Hodi et al. 2010
Toxicidades inmunes
Toxicity kinetics
Weber JS, et al. J Clin Oncol 2012;30:2691–2697 YERVOY SmPC, available at http://www.ema.europa.eu
CTLA-4 y PD-1 Diferente acción sobre el sistema inmune
Toxicity management
Symptomatic treatment Mild
Persistent mild or moderate
Severe , clinical deterioration or
persistent moderate
Oral steroid 1 mg/kg Delay next Ipilimumab dose
High dose IV steroid 2 mg/kg with an slow reduction (1 month) if improvement
Immunosuppressive therapy if no response in 7 days
End Ipilimumab
Weber JS, et al. J Clin Oncol 2012;30:2691–2697 YERVOY SmPC, available at http://www.ema.europa.eu
Predicción de respuesta
Cifra de linfocitos
Ku GY et al. Cancer 2010; 116:1767-1775.
Neo-antigenos y Checkpoint therapy
Neoantigenos y CTLA-4
Carga mutacional y beneficio Ipilimumab
Supervivencia por numero mutaciones
Supervivencia por firma genética de neo-epitopos
Conclusiones anti CTLA-4
• Primer tratamiento sobre punto de control inmunológico
• Mecanismo de acción innovador
• Eficacia clínica demostrada de forma consistente en melanoma
• Patrón especifico de respuesta y toxicidad
• Dificultad predicción de la respuesta